CEPI provides $30m to advance novel coronavirus vaccine
European Pharmaceutical Review
JULY 11, 2022
Many current COVID-19 vaccine candidates work by presenting fragments of the SARS-CoV?2 2 spike (S) protein – the receptor-binding domain (RBD) – to the body to generate an immune response. 2 is the virus that causes COVID-19.). It does this by presenting S protein fragment RBDs from SARS-CoV?2
95 
Let's personalize your content